CONDUIT PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
CONDUIT PHARMACEUTICALS INC. - More news...
CONDUIT PHARMACEUTICALS INC. - More news...
- Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
- Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
- Conduit Progresses Phase II of its AI Initiative with Sarborg
- Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
- Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
- Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
- Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
- Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
- Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
- Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics
- Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
- Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
- Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
- Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
- Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
- Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
- Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
- Conduit Pharmaceuticals to Join Russell 3000® Index
- Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
- Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub
- Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference
- Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656
